We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.


2 October 2019 By Robert Cyran

The $348 bln drugmaker’s low-cost deal to end a suit from two Ohio counties is a sign the painkiller-scandal litigation may cost less than expected. Financial incentives and game theory pressure hard-hit areas to come to terms quickly. Settlements may only partly cover damages.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)